2008•Xinxiang yixueyuan xuebaoRequires access

Clinical observation of fludarabine combined with cyclophosphamide on patients with small lymphotic lymphoma/chronic lymphocytic leukemia

Yinghua Ji

Open publisher page 0 citations

Abstract

Objective To evaluate the therapeutic effect and adverse reaction of fludarabine and cyclophosphamide for treatment of patients with small lymphotic lymphoma/ chronic lymphocytic leukemia(SLL/CLL).Methods Twenty-one patients with SLL/CLL(eleven patients of whom wrere previously untreated and ten of whom were relapsed/refractory) were treated with FC regiment :fludarabine 25~30 mg·m-2,intravenously guttae,from the first day to the third day,and cyclophosphamide 400~600 mg·m-2,intravenously guttae,the first day,21 days was a treatment cycle and repeated for 6 cycles.Results The average course of twenty-one patients were 4.4.The rate of complete respose(CR),partial response(PR) and overall response(OR) was 61.9%(13/21),28.6%(6/21) and 90.5%(19/21) respectively.There were no significant difference in the rate of CR,PR and OR between previously untreated and relapsed/refractory group(63.6%,36.4%,100% vs 60%,20.0%,80.0% respctively,P0.05).The main adverse reactions included myelosuppression and immunosupression.Grade Ⅲ~Ⅳ leukopenia was found in seven(33.3%) patients,and grade Ⅲ~Ⅳ thrombocytopenia in four(19.1%)patients.Infection and fever occurred in seven(33.3%)patients,but no patient died for that.Other toxicities mainly included nausea vomiting and mild liver,kidney function impairment and autoimmune haemolytic anemia.The median follow-up time was 24 months(rang 1~40 months).2 year survival rate was 90.5%(19/21)and 2 year progression free survival rate was 80.9%(17/21).2 year survival rate and progression free survival rate were 100%(11/11) in the previously untreated group.While in the relapsed/refractory group,2 year survival rate and progression free survival rate were 80.0%(8/10)and 60.0%(6/10) respectively.There was no significant difference between the two groups(P0.05).Conclusion The FC combined chemotherapty regiment on patients with SLL/CLL had a good therapeutic effect and few adverse reaction,but more attention should be given to the long-term effect.

About this research paper

What this paper is about

Objective To evaluate the therapeutic effect and adverse reaction of fludarabine and cyclophosphamide for treatment of patients with small lymphotic lymphoma/ chronic lymphocytic leukemia(SLL/CLL).Methods Twenty-one patients with SLL/CLL(eleven patients of whom wrere previously untreated and ten of whom were relapsed/refractory) were treated with FC regiment :fludarabine 25~30 mg·m-2,intravenously guttae,from the first day to the third day,and cyclophosphamide 400~600 mg·m-2,intravenously guttae,the first day,21 days was a treatment cycle and repeated for 6 cycles.Results The average course of twenty-one patients were 4.4.The rate of complete respose(CR),partial response(PR) and overall response(OR) was 61.9%(13/21),28.6%(6/21) and 90.5%(19/21) respectively.There were no significant difference in the rate of CR,PR and OR between previously untreated and relapsed/refractory group(63.6%,36.4%,100% vs 60%,20.0%,80.0% respctively,P0.05).The main adverse reactions included myelosuppression and immunosupression.Grade Ⅲ~Ⅳ leukopenia was found in seven(33.3%) patients,and grade Ⅲ~Ⅳ thrombocytopenia in four(19.1%)patients.Infection and fever occurred in seven(33.3%)patients,but no patient died for that.Other toxicities mainly included nausea vomiting and mild liver,kidney function impairment and autoimmune haemolytic anemia.The median follow-up time was 24 months(rang 1~40 months).2 year survival rate was 90.5%(19/21)and 2 year progression free survival rate was 80.9%(17/21).2 year survival rate and progression free survival rate were 100%(11/11) in the previously untreated group.While in the relapsed/refractory group,2 year survival rate and progression free survival rate were 80.0%(8/10)and 60.0%(6/10) respectively.There was no significant difference between the two groups(P0.05).Conclusion The FC combined chemotherapty regiment on patients with SLL/CLL had a good therapeutic effect and few adverse reaction,but more attention should be given to the long-term effect.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To evaluate the therapeutic effect and adverse reaction of fludarabine and cyclophosphamide for treatment of patients with small lymphotic lymphoma/ chronic lymphocytic leukemia(SLL/CLL).Methods Twenty-one patients with SLL/CLL(eleven patients of whom wrere previously untreated and ten of whom were relapsed/refractory) were treated with FC regiment :fludarabine 25~30 mg·m-2,intravenously guttae,from the first day to the third day,and cyclophosphamide 400~600 mg·m-2,intravenously guttae,the first day,21 days was a treatment cycle and repeated for 6 cycles.Results The average course of twenty-one patients were 4.4.The rate of complete respose(CR),partial response(PR) and overall response(OR) was 61.9%(13/21),28.6%(6/21) and 90.5%(19/21) respectively.There were no significant difference in the rate of CR,PR and OR between previously untreated and relapsed/refractory group(63.6%,36.4%,100% vs 60%,20.0%,80.0% respctively,P0.05).The main adverse reactions included myelosuppression and immunosupression.Grade Ⅲ~Ⅳ leukopenia was found in seven(33.3%) patients,and grade Ⅲ~Ⅳ thrombocytopenia in four(19.1%)patients.Infection and fever occurred in seven(33.3%)patients,but no patient died for that.Other toxicities mainly included nausea vomiting and mild liver,kidney function impairment and autoimmune haemolytic anemia.The median follow-up time was 24 months(rang 1~40 months).2 year survival rate was 90.5%(19/21)and 2 year progression free survival rate was 80.9%(17/21).2 year survival rate and progression free survival rate were 100%(11/11) in the previously untreated group.While in the relapsed/refractory group,2 year survival rate and progression free survival rate were 80.0%(8/10)and 60.0%(6/10) respectively.There was no significant difference between the two groups(P0.05).Conclusion The FC combined chemotherapty regiment on patients with SLL/CLL had a good therapeutic effect and few adverse reaction,but more attention should be given to the long-term effect.

Key concepts: Fludarabine, Medicine, Cyclophosphamide, Gastroenterology, Internal medicine, Leukopenia, Nausea, Vomiting

Related papers

Back to paper searchBrowse research topicsOriginal source
Clinical observation of fludarabine combined with cyclophosphamide on patients with small lymphotic lymphoma/chronic lymphocytic leukemia — Research Paper | ScholarLens